News

Nxera Pharma licenses EP4 agonist NXE0033744 to AbbVie in up to $1.47B IBD deal

What happened: On 4 November 2026, Nxera Pharma signed an exclusive global licence agreement with AbbVie for NXE0033744, an investigational oral EP4 receptor agonist for inflammatory bowel disease (IBD). Nxera receives a US$100 million upfront payment and is eligible for up to US$1.37 billion in development and commercial milestones, plus tiered royalties on net sales.

Why it matters: NXE0033744, discovered on Nxera's NxWave discovery platform, is a potential first-in-class treatment. It is designed to selectively activate EP4 receptors in the gut, dampening inflammation while supporting the intestinal barrier's natural repair and healing — a different mechanism from today's IBD therapies. A completed Phase 1 programme (including a cohort of ulcerative colitis patients) supported a gut-restricted profile and confirmed the drug engages its target. AbbVie takes worldwide development and commercialisation rights in IBD; the deal is subject to antitrust clearance.

Read more: Nxera Pharma via GlobeNewswire, 4 November 2026

More top stories